Green Cross Corp
006280
Company Profile
Business description
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.
Contact
303 Bojeong-Dong
Giheung-Gu
YonginGyeonggi449-070
KORT: +82 312609300
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
2,355
Stocks News & Analysis
stocks
Undervalued ASX share showing progress in global efforts
More clarity on the path forward in the UK.
stocks
Bookworm: Is this the secret to exceptional long-term returns?
Acceptance may be an investor’s best friend.
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 29.90 | 0.33% |
| CAC 40 | 7,834.58 | 16.30 | 0.21% |
| DAX 40 | 24,217.50 | 78.43 | -0.32% |
| Dow JONES (US) | 44,901.92 | 208.01 | 0.47% |
| FTSE 100 | 9,120.31 | 18.06 | -0.20% |
| HKSE | 25,510.31 | 121.96 | 0.48% |
| NASDAQ | 21,108.32 | 50.36 | 0.24% |
| Nikkei 225 | 41,042.20 | 414.03 | -1.00% |
| NZX 50 Index | 12,910.74 | 57.28 | 0.45% |
| S&P 500 | 6,388.64 | 25.29 | 0.40% |
| S&P/ASX 200 | 8,698.70 | 31.80 | 0.37% |
| SSE Composite Index | 3,594.40 | 0.74 | 0.02% |